Clinical trials: Breast Cancer (Early Breast Cancer)
Early or Locally Advanced HER2-positive Breast Cancer
A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer
This randomized, controlled, open-label, multicenter study will evaluate the safety and efficacy of KN026 in combination with HB1801 ± Carboplatin as neoadjuvant therapy in patients with early or locally advanced HER2-positive…
- Trial name
- Neo-Healer (NCT06747338)
- Testing
- KN026, HB1801, Pertuzumab
- Where
- China
- Volunteers
- 520 people
- Sponsor
- Shanghai JMT-Bio Inc.
Breast Cancer
Breast Cancer Screening With MRI in Women Aged 50-75 Years With Extremely Dense Breast Tissue: the DENSE Trial
The purpose of this study is to determine the cost-effectiveness of biennial screening with mammography and MRI compared to mammography alone in women aged 50-75 years and who show > 75% mammographic density.
- Trial name
- NCT01315015
- Testing
- Contrast enhanced breast MRI
- Where
- 9 sites in Netherlands
- Volunteers
- 40,373 people
- Sponsor
- UMC Utrecht
Breast Cancer
Docetaxel,Carboplatin,Trastuzumab and Bevacizumab for Breast Cancer and Bone Marrow Micrometastases
RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00949247
- Testing
- bevacizumab, trastuzumab, carboplatin
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- Case Comprehensive Cancer Center
Breast Cancer
Evaluation for the Effectiveness and Safety of Cryo-ablation in the Treatment of Early Invasive Breast Cancer
Recently, researchers in America reported a clinical research (Alliance Z1072) which proved that cryo-ablation could be considered as a non-surgical treatment of early-stage breast cancer.
- Trial name
- NCT04334785
- Testing
- cryo-ablation
- Where
- China
- Volunteers
- 186 people
- Sponsor
- Fudan University
Breast Cancer, Early-stage Breast Cancer
Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer
This is a prospective, single-center, randomize-controlled study. The purpose of this study is to evaluate the efficacy of neoadjuvant CDK4/6 inhibitors in patients with high-risk EPclin multigene risk analysis and non-response…
- Trial name
- NeoMARS (NCT06650748)
- Testing
- Dalpiciclib, Letrozole
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University
Breast Cancer, Myocardial Fibrosis
Losartan in Prevention of Radiation-Induced Heart Failure
This study is being done to see if losartan affects the chances of developing radiation-induced heart failure in patients who are receiving radiation therapy as part of standard of care treatment for breast cancer.
- Conditions
- Breast Cancer, Myocardial Fibrosis, Radiation-Induced Fibrosis
- Trial name
- NCT05607017
- Testing
- Losartan, Radiation Therapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Massachusetts General Hospital
HER2-positive Breast Cancer
A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC
To evaluate the pathology complete response rate (pathology Complete Response, pCR) of eribulin combined with trastuzumab + pertuzumab in neoadjuvant therapy for HER-2 positive early or locally advanced breast cancer.
- Trial name
- NCT05945368
- Testing
- Eribulin mesylate injection、Pertuzumab、Trastuzumab
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Early Stage Breast Carcinoma
Sentinel Node Vs Observation After Axillary Ultra-souND
The hypothesis of this trial are that: avoiding axillary surgery does not worsen the outcome of patients with small breast cancer the absence of the pathological information on the risk of recurrence given by nodal status is not…
- Trial name
- SOUND (NCT02167490)
- Testing
- Arm 1: sentinel node biopsy
- Where
- 18 sites in Chile, Italy and 2 more
- Volunteers
- 1,560 people
- Sponsor
- European Institute of Oncology
Breast Cancer Recurrent
Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC
This is a prospective phase 2 study to use Functional Precision Oncology (FPO) to predict, prevent and treat early metastatic recurrence in subjects with HR-low/Her2 negative or triple negative breast cancer.
- Trial name
- TOWARDS-II (NCT05464082)
- Testing
- Functional Precision Oncology
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Utah
Neutropenia, Breast Cancer
SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide
The purpose of this study is to compare the efficacy of SPI-2012 versus pegfilgrastim in participants with early-stage breast cancer receiving docetaxel and cyclophosphamide (TC) as measured by the duration of severe neutropenia…
- Trial name
- NCT02953340
- Testing
- SPI-2012, Pegfilgrastim, Docetaxel
- Where
- 74 sites in United States, Canada and 4 more
- Volunteers
- 237 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Breast Cancer
A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer
Choice Of the Most Active Strategies for Short term recurring Triple Negative Breast Cancer: A phase Ib/II, open-label, modular, dose-finding and dose-expansion study to explore safety, tolerability, pharmacokinetics, and…
- Trial name
- COMPASS-TNBC (NCT06508216)
- Testing
- Dato-DXd, Durvalumab
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Breast Cancer
Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer
RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- EPHOS-B (NCT01104571)
- Testing
- trastuzumab, lapatinib ditosylate, laboratory biomarker analysis
- Where
- United Kingdom
- Volunteers
- 257 people
- Sponsor
- Institute of Cancer Research, United Kingdom
HR+/HER2- Early Breast Cancer
Patient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast Cancer
The goal of this observational study is to evaluate how persistently patients with high-risk early breast cancer take abemaciclib 6 months after therapy start.
- Trial name
- PROSPER (NCT07531693)
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Institut fuer Frauengesundheit
Breast Cancer
Creatine and Cognitive Health in Patients With Early-stage Breast Cancer During and After Chemotherapy Treatment
The goal of this clinical trial is to evaluate whether oral creatine supplementation can prevent chemotherapy-related cognitive impairment in patients with early-stage breast cancer undergoing neoadjuvant or adjuvant…
- Trial name
- IARA (NCT07372144)
- Testing
- Creatine
- Where
- Brazil
- Volunteers
- 227 people
- Sponsor
- D'Or Institute for Research and Education
Breast Carcinoma, Carcinoma of Unknown Primary
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
This phase I trial studies the side effects and the best dose of veliparib when given together with paclitaxel and carboplatin in treating patients with solid tumors that are metastatic or cannot be removed by surgery and liver…
- Conditions
- Breast Carcinoma, Carcinoma of Unknown Primary, Endometrial Carcinoma, Esophageal Carcinoma
- Trial name
- NCT01366144
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 17 sites in United States
- Volunteers
- 94 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer
This is a non-randomized, Phase II study. Efficacy is not a primary endpoint in this study; however, progression-free survival will be followed and determined for the patients in this study.
- Trial name
- NCT00629499
- Testing
- nab paclitaxel, Cyclophosphamide, Trastuzumab
- Where
- 10 sites in United States
- Volunteers
- 63 people
- Sponsor
- SCRI Development Innovations, LLC
Breast Cancer, Triple Negative Breast Neoplasms
A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer
The primary purpose of this research study is to see whether adding bavituximab (an investigational drug) to the standard chemotherapy drug taxane, will improve the results of the treatment for early- stage Triple Negative Breast…
- Conditions
- Breast Cancer, Triple Negative Breast Neoplasms, Triple-Negative Breast Neoplasm, Triple-Negative Breast Cancer
- Trial name
- NCT02685306
- Testing
- Bavituximab, Taxane
- Sponsor
- Peregrine Pharmaceuticals
CIPN - Chemotherapy-Induced Peripheral Neuropathy
Study to Investigate the Chemotherapy-Induced Peripheral Neuropathy (CIPN) Onset-Suppressing Effect and Safety of ONO-2910 in Patients With Breast Cancer Receiving Weekly Paclitaxel
To investigate the safety and CIPN onset-suppressing effect of ONO-2910 in participants receiving paclitaxel (PTX) weekly as chemotherapy for breast cancer in Japan.
- Trial name
- NCT06538272
- Testing
- ONO-2910
- Where
- 30 sites in Japan
- Volunteers
- 210 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Breast Cancer
Longitudinal Evaluation of Taxane Induced Neuropathy in Early Stage Breast Cancer
Longitudinal Evaluation of Taxane induced neuropathy in early stage breast cancer.
- Trial name
- NCT02125019
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Breast Cancer
Neoadjuvant Inetetamab and Pyrotinib and Nab-paclitaxel for HER2+Breast Cancer
Explore the efficacy and safety of the combination of inetetamab, pyrotinib and nab-paclitaxel in the neoadjuvant treatment of HER2 positive early or locally advanced breast cancer
- Trial name
- NCT05444998
- Testing
- Inetetamab, pyrotinib, nab-paclitaxel
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xijing Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.